Canada pushes ADR reporting with new national initiative
This article was originally published in Scrip
Executive Summary
The Canadian government is making a new bid to tackle under-reporting of suspected adverse drug reactions (ADRs), with the launch of a marketing initiative designed to encourage reporting awareness.